OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX) in a report released on Tuesday morning. The brokerage issued a sell rating on the stock.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $4.25 price target on shares of OncoCyte in a research note on Wednesday, November 13th.

OncoCyte Stock Down 4.2 %

NASDAQ:OCX opened at $2.53 on Tuesday. The company has a 50-day moving average price of $2.96 and a 200-day moving average price of $2.98. OncoCyte has a 12 month low of $2.29 and a 12 month high of $4.30.

OncoCyte (NASDAQ:OCX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.54). OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. The company had revenue of $0.12 million during the quarter. During the same period in the previous year, the business earned ($0.57) EPS.

Insider Buying and Selling at OncoCyte

In other news, CFO Andrea S. James bought 33,670 shares of the stock in a transaction on Wednesday, October 2nd. The shares were bought at an average price of $2.97 per share, with a total value of $99,999.90. Following the completion of the acquisition, the chief financial officer now owns 33,670 shares in the company, valued at $99,999.90. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was acquired at an average cost of $2.95 per share, for a total transaction of $3,880,250.05. Following the acquisition, the insider now owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. The trade was a 26.69 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.58% of the company’s stock.

Institutional Investors Weigh In On OncoCyte

An institutional investor recently raised its position in OncoCyte stock. Geode Capital Management LLC lifted its stake in shares of OncoCyte Co. (NASDAQ:OCX) by 12.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 103,980 shares of the company’s stock after acquiring an additional 11,289 shares during the quarter. Geode Capital Management LLC owned approximately 0.62% of OncoCyte worth $296,000 at the end of the most recent reporting period. Institutional investors own 55.35% of the company’s stock.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.